DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) posted Total Non-Current Liabilities of $8.5 million for Q2 2026, up 26.87% sequentially from $6.7 million in Q1 2026, and up 9.25% YoY from $7.8 million in Q2 2025.
DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies has reported Total Non-Current Liabilities for 12 years, with the latest figure at $8.5 million in Q2 2026.
- Quarterly Total Non-Current Liabilities rose 9.25% year-over-year to $8.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.5 million (up 9.25% YoY) and the FY2025 annual result came in at $6.9 million, down 3.29% from the prior year.
- Total Non-Current Liabilities improved to $8.5 million in Q2 2026 per DBVT's latest filing, from $6.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $22.5 million in Q4 2022 and troughed at $5.5 million in Q4 2023.
- A 5-year average of $10.4 million and a median of $7.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 121.92% in 2023, down 75.78% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $22.5 million in 2022, then sank by 75.78% to $5.5 million in 2023, then soared by 30.65% to $7.1 million in 2024, then dropped by 3.29% to $6.9 million in 2025, then climbed by 23.19% to $8.5 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.5 million, $6.7 million, and $6.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.50 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 7.78 Mn |
| Mar 31, 2025 | 7.31 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 5.46 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 19.91 Mn |
| Mar 31, 2023 | 21.06 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 10.13 Mn |
| Mar 31, 2022 | 9.49 Mn |
| Dec 31, 2021 | 16.05 Mn |
| Sep 30, 2021 | 20.22 Mn |